Global Cell Penetrating Peptide Market to be dominated by Peptide-based CPPs through 2028
Rising adoption of
peptides in pharmaceutical and consumer healthcare are expected to drive the
Global Cell Penetrating Peptide Market growth in the forecast period,
2024-2028.
According to TechSci Research report, “Cell Penetrating Peptide Market - Global Industry Size, Share, Trends, Opportunity,
and Forecast, 2018-2028F”, Global Cell Penetrating Peptide Market
stood at USD1607.26 Million in 2022 and is anticipated to grow at an impressive
rate of around 10.47% in the forecast period, 2024-2028. The market for Cell
Penetrating Peptide devices has witnessed consistent growth over the Rising
Demand for Targeted Drug Delivery. The versatility of CPPs has led to their
adoption in a wide range of therapeutic areas, including oncology,
neurodegenerative diseases, infectious diseases, and regenerative medicine. As
research continues to uncover novel applications, the market is benefiting from
a growing pipeline of CPP-based therapies. Recent developments in peptide
synthesis techniques and chemical modification strategies have enabled the design
of CPPs with improved stability, specificity, and delivery efficiency. These
advancements have boosted the development of next-generation CPPs, further
propelling market growth. The global prevalence of chronic diseases, such as
cancer and cardiovascular disorders, continues to rise. CPPs offer a promising
avenue for the delivery of innovative therapies that can address unmet medical
needs in these disease areas, driving market growth. The trend toward
personalized medicine, where treatments are tailored to individual patient
characteristics, has led to increased interest in targeted drug delivery
methods like CPPs. These peptides can be engineered to selectively deliver
therapeutics to specific cell types or tissues, aligning with the principles of
personalized medicine.
Also, owing to stringent regulations and
the high cost of outsourcing can hamper the growth of Global Cell Penetrating
Peptide Market. Similarly, a lack of skilled professionals can restrain the
growth of Global Cell Penetrating Peptide Market. Additionally, Limited
Clinical Data will further restrict the growth of Global Cell Penetrating
Peptide Market.
Browse over xx market
data Figures spread through 160 Pages and an in-depth TOC
on "Global Cell Penetrating Peptide Market.”
The Global Cell Penetrating Peptide
Market is segmented into Type, Application,
End user and Region.
Based on End User, Global
Cell Penetrating Peptide market is segmented into Pharmaceutical and Biotechnology
Companies, Contract Research Organizations (CROs), Hospitals, and Clinics. The Pharmaceutical
and Biotechnology Companies segment accounted for the largest revenue share in
2022 and is expected to exhibit a rapid CAGR over the forecast period. This can
be attributed to the increasing usage of peptides in pharmaceutical companies.
Pharmaceutical
companies drive CPP-based therapies through clinical trial phases and navigate
the complex regulatory landscape. Their expertise in designing and conducting
clinical trials is essential for demonstrating safety, efficacy, and compliance
with regulatory requirements. Pharmaceutical and biotechnology companies
also contribute to educational initiatives, conferences, and workshops focused
on CPPs. These platforms facilitate knowledge sharing, promote scientific
discourse, and encourage the development of a skilled workforce.
Major companies operating in Global Cell Penetrating Peptide Market are:
- The Cupid Peptide Company.
- AltaBioscience Ltd.
- AnaSpec Inc.
- Peptomyc.
- Amidebio LLC
- Biopeptide Co LLC
- AAPPTec
- CSBio Company Inc
- CEM Corporation
- Bachem Holding AG
Download Free Sample Report
Customers can also request for 10% free customization on this report.
In MAY 2022, Bristol Myers Squibb and LOTTE
Corporation stated that LOTTE has decided to acquire Bristol Myers Squibb's
East Syracuse, New York-based production plant. The East Syracuse location will
house LOTTE's novel biologics CDMO business in the U.S. In February 2022, Amgen
and Plexium, Inc. revealed a multi-year research collaboration and license
agreement to generate new targeted protein degradation therapeutics for
previously difficult drug targets.
In March 2023, Ono Pharmaceuticals and PeptiDream
entered into a collaboration for the drug discovery and development of
Macrocyclic Constrained Peptide Therapeutics.
“The North
America region is expected to witness significant growth of Global Cell
Penetrating Peptide market due to the rising R&D spending by key players. North
America stands out as a dominant force, driving substantial growth and
innovation. The region's leadership is attributed to a convergence of factors
that foster an environment conducive to CPP advancements. North America boasts
a robust biotechnology and pharmaceutical industry, characterized by extensive
research infrastructure, strategic investments, and a culture of innovation.
Furthermore, strong collaborations between academia, research institutions, and
industry players have propelled the development of novel CPP-based therapies.
Access to a skilled talent pool and favorable regulatory frameworks has
expedited clinical translation and commercialization. With a focus on
personalized medicine and a penchant for cutting-edge technologies, North America's
contribution to CPP research, development, and market expansion remains a key
driver in shaping the future of this dynamic field. Increasing
demand from life sciences, biotechnology, and food & beverages industries
is the major factor driving the growth of the global Cell Penetrating Peptide
Market during the forecast period” said Mr. Karan Chechi, Research Director
with TechSci Research, a research-based management consulting firm.
“Cell Penetrating Peptide Market - Global Industry
Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type
(Protein-based CPPs, Peptide-based CPPs), By Application (Drug Delivery, Gene
Delivery, Diagnostics, Molecular Imaging, Others (Vaccine development,
Antimicrobial Therapy), By End User (Pharmaceutical and Biotechnology
Companies, Contract Research Organizations (CROs), Hospitals, and Clinics), By Region and Competition”,
has evaluated the future growth potential of Global Cell Penetrating Peptide Market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Cell Penetrating Peptide Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com